Differences among young adults, adults and elderly chronic myeloid leukemia patients

被引:71
作者
Castagnetti, F. [1 ]
Gugliotta, G. [1 ]
Baccarani, M. [2 ]
Breccia, M. [3 ]
Specchia, G. [4 ]
Levato, L. [5 ]
Abruzzese, E. [6 ]
Rossi, G. [7 ]
Iurlo, A. [8 ]
Martino, B. [9 ]
Pregno, P. [10 ]
Stagno, F. [11 ]
Cuneo, A. [12 ]
Bonifacio, M. [13 ]
Gobbi, M. [14 ]
Russo, D. [15 ]
Gozzini, A. [16 ]
Tiribelli, M. [17 ]
de Vivo, A. [1 ]
Alimena, G. [3 ]
Cavo, M. [1 ]
Martinelli, G. [1 ]
Pane, F. [18 ]
Saglio, G. [19 ]
Rosti, G. [1 ]
机构
[1] S Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] Univ Bologna, Dept Hematol & Oncol L&A Seragnoli, I-40138 Bologna, Italy
[3] Univ Roma La Sapienza, Hematol Sect, Dept Biotechnol & Cellular Hematol, Rome, Italy
[4] Univ Bari, Chair Hematol, Bari, Italy
[5] Pugliese Ciaccio Hosp, Hematol Unit, Catanzaro, Italy
[6] S Eugenio Hosp, Hematol Unit, Rome, Italy
[7] Azienda Osped Spedali Civili, Hematol Unit, Brescia, Italy
[8] IRCCS Ca Granda Maggiore Univ Hosp, Div Oncohematol, Elderly Unit, Milan, Italy
[9] Azienda Osped Bianchi Melacrino Morelli, Hematol Unit, Reggio Di Calabria, Italy
[10] Azienda Osped Univ Citta Salute Sci, Hematol Unit, Turin, Italy
[11] Univ Catania, Dept Biomed Sci, Hematol Sect, Catania, Italy
[12] Univ Ferrara, Azienda Osped Univ Arcispedale S Anna, Chair Hematol, I-44100 Ferrara, Italy
[13] Univ Verona, Dept Med, Hematol Sect, I-37100 Verona, Italy
[14] IRCCS AOU San Martino IST, Clin Hematol Unit, Genoa, Italy
[15] Univ Brescia, Azienda Osped Spedali Civili, Blood Dis & Stem Cell Transplantat Unit, Brescia, Italy
[16] Careggi Univ Hosp, Hematol Unit, Florence, Italy
[17] S Maria Della Misericordia Univ Hosp, Hematol Unit, Udine, Italy
[18] Univ Naples Federico II, Dept Biochem & Med Biotechnol, Hematol Sect, Naples, Italy
[19] Univ Torino, S Luigi Gonzaga Univ Hosp, Dept Clin & Biol Sci, Orbassano, Italy
关键词
chronic myeloid leukemia; BCR-ABL; prognosis; young adults; tyrosine kinase inhibitors; CHRONIC MYELOGENOUS LEUKEMIA; IMATINIB TREATMENT; CLINICAL-TRIALS; BONE-MARROW; SURVIVAL; CML; RECOMMENDATIONS; MANAGEMENT; SPLEEN; LIVER;
D O I
10.1093/annonc/mdu490
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 25 条
[1]   How I treat childhood CML [J].
Andolina, Jeffrey R. ;
Neudorf, Steven M. ;
Corey, Seth J. .
BLOOD, 2012, 119 (08) :1821-1830
[2]  
Baccarani M, 1975, Ser Haematol, V8, P81
[3]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[4]   European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].
Baccarani, Michele ;
Deininger, Michael W. ;
Rosti, Gianantonio ;
Hochhaus, Andreas ;
Soverini, Simona ;
Apperley, Jane F. ;
Cervantes, Francisco ;
Clark, Richard E. ;
Cortes, Jorge E. ;
Guilhot, Francois ;
Hjorth-Hansen, Henrik ;
Hughes, Timothy P. ;
Kantarjian, Hagop M. ;
Kim, Dong-Wook ;
Larson, Richard A. ;
Lipton, Jeffrey H. ;
Mahon, Francois-Xavier ;
Martinelli, Giovanni ;
Mayer, Jiri ;
Mueller, Martin C. ;
Niederwieser, Dietger ;
Pane, Fabrizio ;
Radich, Jerald P. ;
Rousselot, Philippe ;
Saglio, Giuseppe ;
Saussele, Susanne ;
Schiffer, Charles ;
Silver, Richard ;
Simonsson, Bengt ;
Steegmann, Juan-Luis ;
Goldman, John M. ;
Hehlmann, Ruediger .
BLOOD, 2013, 122 (06) :872-884
[5]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[6]  
Chapman WC, 1999, WINTROBES CLIN HEMAT, P1969
[7]   Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party [J].
Gugliotta, Gabriele ;
Castagnetti, Fausto ;
Palandri, Francesca ;
Breccia, Massimo ;
Intermesoli, Tamara ;
Capucci, Adele ;
Martino, Bruno ;
Pregno, Patrizia ;
Rupoli, Serena ;
Ferrero, Dario ;
Gherlinzoni, Filippo ;
Montefusco, Enrico ;
Bocchia, Monica ;
Tiribelli, Mario ;
Pierri, Ivana ;
Grifoni, Federica ;
Marzocchi, Giulia ;
Amabile, Marilina ;
Testoni, Nicoletta ;
Martinelli, Giovanni ;
Alimena, Giuliana ;
Pane, Fabrizio ;
Saglio, Giuseppe ;
Baccarani, Michele ;
Rosti, Gianantonio .
BLOOD, 2011, 117 (21) :5591-5599
[8]   Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet [J].
Guilhot, Joelle ;
Baccarani, Michele ;
Clark, Richard E. ;
Cervantes, Francisco ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Kulikov, Sergei ;
Mayer, Jiri ;
Petzer, Andreas L. ;
Rosti, Gianantonio ;
Rousselot, Philippe ;
Saglio, Giuseppe ;
Saussele, Susanne ;
Simonsson, Bengt ;
Steegmann, Juan-Luis ;
Zaritskey, Andrey ;
Hehlmann, Ruediger .
BLOOD, 2012, 119 (25) :5963-5971
[9]   Childhood CML in India: b2a2 transcript is more common than b3a2 [J].
Hasan, Syed Khizer ;
Sazawal, Sudha ;
Kumar, Bijender ;
Chaubey, Rekha ;
Mishra, Pravas ;
Mir, Rashid ;
Chaudhry, Ved Prakash ;
Saxena, Renu .
CANCER GENETICS AND CYTOGENETICS, 2006, 169 (01) :76-77
[10]   A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa [J].
Hasford, J ;
Pfirrmann, M ;
Hehlmann, R ;
Allan, NC ;
Baccarani, M ;
Kluin-Nelemans, JC ;
Alimena, G ;
Steegmann, JL ;
Ansari, H .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :850-858